The SHERPA research consortium has initiated seven clinical studies to validate AI- and robotics-assisted workflows for minimally invasive treatment of brain aneurysms and tumors.
With a total budget of EUR 21.5 million, the project is co-funded by the EU Innovative Health Initiative (IHI) and industry partners. It aims to address one of the most pressing challenges in interventional radiology and neurointervention: increasing procedural complexity combined with workforce shortages.
Following its development phase, SHERPA now enters clinical validation. The seven studies include five focused on brain aneurysm care and two addressing liver and lung tumor interventions. The neurovascular trials evaluate AI-driven aneurysm detection, rupture risk prediction, device selection guidance, imaging optimisation and structured digital follow-up.
The five brain aneurysm studies are:
- RADAR – AI-based aneurysm detection on CT and MR imaging
- Aneurysm@risk – AI-driven prediction of aneurysm growth and rupture risk
- ASSIST – AI-supported device selection and positioning guidance during treatment
- INTERACT – automated collimation and projection angle optimisation for procedural imaging
- SAFO – digital remote follow-up solution for standardized aneurysm monitoring
Together, these technologies are designed to support decision-making, streamline complex workflows and improve precision across the entire neurointerventional pathway.
As a partner, ESMINT contributes its scientific expertise and professional network to ensure that SHERPA innovations remain aligned with real-world neurointerventional practice and the needs of multidisciplinary teams across Europe.
SHERPA will also be presented at the European Congress of Radiology 2026 in a dedicated session highlighting AI-powered assistive technologies for interventional workflows.
Read the full press release here: SHERPA Press Release ESMINT 02032026
Learn more about the SHERPA project.
